Director/PDMR Shareholding

RNS Number : 1150E

Hemogenyx Pharmaceuticals PLC

07 February 2018

 

Hemogenyx Pharmaceuticals Plc

("Hemogenyx" or the "Company")

Director/PDMR Shareholding

CEO and Co-founder buys shares

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that on 5 February 2018 Dr Vladislav Sandler, Chief Executive Officer and Co-Founder of the Company, purchased 26,800 ordinary shares of £0.01 in the Company ("Ordinary Shares") at a price of 2.37 pence per Ordinary Share.

Following this transaction, Dr Sandler now holds 40,478,010 Ordinary Shares, representing approximately 11.37% of the Company's issued share capital.

The Notification of Dealing Forms provided in accordance with the requirements of MAR in relation to the transactions listed above are set out below:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Vladislav Sandler
2	Reason for the notification
a)	Position/status	Chief Executive Officer and Co-Founder
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hemogenyx Pharmaceuticals Plc
b)	LEI	n/a
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of £0.01 each
	Identification code	ISIN GB00BYX3WZ24
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			2.37p	26,800
d)	Aggregated information
	- Aggregated volume	N/A - single transaction
	- Price
e)	Date of the transaction	5 February 2018
f)	Place of the transaction	London Stock Exchange

Enquiries:

Hemogenyx Pharmaceuticals Limited		www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder		Via Walbrook PR
Dr Robin Campbell, Chairman
Optiva Securities Ltd		Tel: [phone]
Christian Dennis
Shard Capital Partners LLP		Tel: [phone]
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Limited		Tel: [phone]
Lucy Williams/Duncan Vasey
Walbrook PR (UK Media & Investor Relations)	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
US Media enquiries
Lowell Goodman	Tel: [phone] or [e-mail]

About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York.

HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care.

For more information, visit www.hemogenyx.com.

 

END

 

 

DSHBIGDDLDGBGIL